A report in September 2009 from Health and Human Services' Agency for Healthcare Research and Quality suggests that tamoxifen, raloxifene, and<unk>  used to reduce the risk of breast cancer significantly reduce the occurrence of invasive breast cancer in midlife and older women, but also increase the risk of adverse effects.<unk>  can infrequently produce androgenic side effects such as acne and increased facial hair growth. Such side effects have been found to occur in 3 to 6% of treated women. A 2016 Cochrane review has been published on the short-term and long-term effects of<unk> , including adverse effects. Possible adverse effects of<unk>  include unscheduled vaginal bleeding ( = 2.79; incidence 13–26% more than placebo), an increased risk of breast cancer in women with a history of breast cancer ( = 1.5) although apparently not without a history of breast cancer ( = 0.52), an increased risk of cerebrovascular events (strokes) ( = 1.74) and cardiovascular events ( = 1.38), and an increased risk of endometrial cancer ( = 2.04). However, most of these figures are based on very low-quality evidence.<unk>  has been associated with increased risk of endometrial cancer in most studies.
Tibolone
Quinbolone
Oxendolone
Diprobase
Oxytetracycline
Aminophenazone
Sulfadiazine
Revefenacin